Antibody prevalence in epilepsy and response to immunotherapy in epilepsy scores: primer for “Predictive models in the diagnosis and treatment of autoimmune epilepsy”
Rishika Quick-Singh
Abstract
It is only in recent years that epilepsy has been looked at as a symptom of autoimmune responses. Autoimmune epilepsy is very easily misdiagnosed, as the symptoms are often identical to epilepsy with a neurological origin. The purpose of this primer is to provide context to the importance of predictive models, specifically using Antibody Prevalence in Epilepsy (APE) scores and Response to Immunotherapy in Epilepsy (RITE) scores, in the diagnosis and treatment of autoimmune epilepsy. In the original research by Dubey et al. (2017a), APE scores were developed as a predictive model for antibody positivity, and this score was further refined into RITE scores to predict immunotherapy response. Among 1,736 total patients, those who received immunotherapy as a result of the RITE scoring system saw a decrease in seizure recurrence by more than 50%.
